Comparison
1-Methylnicotinamide vs NMN
Vascular protection vs. NAD+ restoration — different tools for different stacks.
1-Methylnicotinamide
Endothelial / Cardiovascular Adjunct
NMN
NAD+ Precursor
Effectiveness Profile
At a Glance
| 1-Methylnicotinamide | NMN | |
|---|---|---|
| Type | Longevity | Longevity |
| Legal status | OTC | Grey-Market |
| Half-life | 3–5 hours | ~15 minutes (plasma NMN); NAD+ elevation persists 24h+ |
| Preferred route | Oral | Oral |
| Dose frequency | twice-daily | once-daily |
| Beginner dose | 50–100 mg | 250–500 mg |
| Intermediate dose | 200–400 mg | 500–750 mg |
| Advanced dose | 500–1000 mg | 750–1000 mg |
| Cycle length | 4–16 wks | 8–52 wks |
| Bioavailability | 85% | 75% |
| Time to peak | 0.75h | 2h |
| Active duration | 6h | 24h |
| Storage | Room temperature, dry, protected from light | Room temperature, sealed, dry; refrigerate for long-term storage |
| PCT required | No | No |
| Ancillaries required | No | No |
| Safe for women | Yes | Yes |
Verdict
1-Methylnicotinamide wins for cardiovascular support, real-world endothelial protection, additive benefits with tadalafil or bergamot, and targeted use during oral-heavy cycles. Mechanistically, it's the only N-niacin metabolite shown to upregulate prostacyclin (PGI₂) for vessel resilience, making it valuable in stacks prone to blood pressure spikes or endothelial stress.
NMN wins for NAD⁺ pool restoration, daily baseline metabolic support, and robust evidence in raising sirtuin activity and whole-blood NAD+. It's the clear choice when declining NAD⁺, impaired recovery, or pure longevity support is the core goal, and integrates seamlessly into both TRT and longevity stacks with minimal side effect risk.
Pick A or B?
Pick 1-Methylnicotinamide if:
- Endothelial function and vascular protection are primary (e.g. running orals, hypertensive-prone cycles).
- Tadalafil or bergamot is part of the stack and additive cardiovascular coverage is wanted.
- Niacin flush is intolerable or unworkable, but vascular benefit is still needed.
- Endurance blocks demand improved recovery and vessel flexibility.
- Platelet aggregation needs to be managed alongside other anti-platelet agents (with care).
Pick NMN if:
- NAD⁺ depletion from age, heavy training, or PEDs is the concern and boosting whole-blood NAD⁺ is the target.
- Recovery, metabolic resilience, or mitochondrial health are the primary outcome measures.
- The protocol follows a daily longevity stack (e.g. with resveratrol or TMG) and seeks comprehensive repair support.
- Human RCT evidence is a must-have for dosing confidence.
- Pure vascular modulation is less important than broad-spectrum cell health.